Form 4: Amgen EVP Bradner's Future Stock Withholding for Taxes

Amgen's EVP of Research and Development, James E. Bradner, reported a future disposition of common stock for tax obligations on February 9, 2026.

Summary

• James E. Bradner, EVP, Research and Development at Amgen Inc., reported a disposition of common stock.
• On February 9, 2026, 2,151 shares of Amgen common stock were disposed of at a price of $384.32 per share.
• On the same date, an additional 953 shares of Amgen common stock were disposed of at a price of $384.32 per share.
• These dispositions were for the payment of tax liability, indicated by Transaction Code 'F'.
• Following these transactions, James E. Bradner beneficially owns 27,378 shares of Amgen common stock.
• The shares beneficially owned include 1,205 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited on unvested RSUs and paid out in shares upon vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine tax withholding associated with the vesting of executive equity awards, indicating ongoing compensation and retention of a key executive.

Positives

• The transaction is a routine tax withholding, indicating the vesting of previously granted equity awards, which is a positive for the executive as it represents realized compensation.

Negatives

• A reduction in direct share ownership, although for a non-discretionary tax purpose, means fewer shares are held by the executive.

Future Outlook

The filing indicates a pre-planned future transaction for tax withholding related to equity awards, suggesting continued vesting of executive compensation.

Industry Context

StockSavvy.ai notes that routine tax withholdings upon equity award vesting are standard practice across the biotechnology and pharmaceutical industries for executive compensation. This transaction reflects the normal course of an executive's equity compensation plan at a major pharmaceutical company like Amgen.

Comparison to Industry Standards

• This type of transaction, where shares are withheld to cover tax obligations upon the vesting of restricted stock units (RSUs), is a common and widely accepted practice in executive compensation across publicly traded companies, particularly in the high-value biopharmaceutical sector.
• Companies like Pfizer, Johnson & Johnson, and Merck routinely structure their executive equity awards with similar tax withholding mechanisms.
• The reported share price of $384.32 for Amgen stock is consistent with the valuation of a leading biopharmaceutical company, reflecting its market position and financial performance relative to peers.

Related Party Transactions

• The disposition of shares by an executive officer (James E. Bradner) for tax purposes related to equity awards granted by Amgen Inc. constitutes a related party transaction, as it involves an insider and the company's securities.

Stakeholder Impact

• Shareholders: The transaction is a routine, non-discretionary event and is unlikely to have a significant direct impact on share price or company operations. It reflects standard executive compensation practices.
• Employees: No direct impact on general employees.
• Management: The transaction reflects the vesting of equity compensation for a key executive, which is part of their overall compensation package and retention strategy.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares for tax withholding purposes by a key executive. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

Amgen, AMGN, Insider Transaction, Form 4, Stock Disposition, Tax Withholding, Executive Compensation, James E. Bradner, Equity Incentive Plan, Dividend Equivalents